- AstraZeneca's SERENA-6 Phase III trial shows promising results for camizestrant in breast cancer treatment.
- Analysts forecast a significant potential upside for AstraZeneca's stock.
- Current recommendation indicates an "Outperform" status.
AstraZeneca PLC (AZN, Financial) has recently unveiled encouraging interim data from its SERENA-6 Phase III trial, spotlighting the potential of camizestrant as a first-line therapy for ER-positive/HER2-negative breast cancer. While the investigational drug has showcased significant progression-free survival advantages, further scrutiny is required to substantiate its overall survival benefits.
Wall Street Analysts Forecast
The latest insights from 10 analysts reveal a one-year average price target for AstraZeneca PLC (AZN, Financial) at $87.28, with projections ranging from a high of $97.00 to a low of $67.00. This average target forecasts an exciting potential upside of 34.49% over the current stock price of $64.90. For a more comprehensive view, visit the AstraZeneca PLC (AZN) Forecast page.
Drawing from evaluations by 12 brokerage firms, the consensus recommendation for AstraZeneca PLC's (AZN, Financial) stock stands at an average of 1.8. This places the stock in the "Outperform" category, according to a scale where 1 equates to Strong Buy and 5 indicates a Sell.
According to GuruFocus estimates, the projected GF Value for AstraZeneca PLC (AZN, Financial) in a year's time is $86.83. This estimation suggests a promising upside of 33.79% from the present price of $64.90. The GF Value is an estimation of the fair trading value, derived from the stock's historical trading multiples, past business growth, and anticipated future business performance. More detailed information is accessible on the AstraZeneca PLC (AZN) Summary page.
